Vialwirebiotech, curated
July 3, 2026, 6:54 PM
May 18, 2026
- 6:08 PM · STAT News6:08 PMSTAT+: Maryland state affordability board places a price cap on Ozempic — STAT News
- 5:29 PM · TechCrunch
- 2:21 PM · Endpoints News2:21 PMAmgen stands by rare disease drug Tavneos amid Japan liver toxicity report — Endpoints News
- 12:00 PM · BioWorld12:00 PMBoston Sci invests $1.5B in Mirus, gains option for TAVR system — BioWorld
- 12:00 PM · BioWorld12:00 PMRegeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis — BioWorld
- 12:00 PM · BioWorld12:00 PMUS Supreme Court swats down several biopharma IRA challenges — BioWorld
- 10:44 AM · Endpoints News10:44 AMMerck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule — Endpoints News
- 9:00 AM · BioWorld
- 9:00 AM · BioWorld9:00 AMIND-enabling studies of adult RPE stem cell product for dry AMD — BioWorld
- 9:00 AM · BioWorld9:00 AMHarbour Biomed’s LET-003 shows promise for obesity — BioWorld
- 9:00 AM · BioWorld9:00 AMGPX-002 restores β-cell function in a diabetes model — BioWorld
- 9:00 AM · BioWorld9:00 AMMD Anderson gains IND nod for CD94-targeted CAR T therapy — BioWorld
- 7:00 AM · Drug Discovery World7:00 AMCytiva’s transcient cell line receives FDA AMT designation — Drug Discovery World
- 6:34 AM · Endpoints News6:34 AMRegeneron's Phase 3 skin cancer miss adds to mounting failures in LAG-3 — Endpoints News
- 6:01 AM · Endpoints News6:01 AMFDA approves AstraZeneca’s baxdrostat for certain patients with hypertension — Endpoints News
- 6:00 AM · Drug Discovery World6:00 AMGSK signs agreement to streamline clinical trials — Drug Discovery World
- 6:00 AM · Pharmaceutical Executive6:00 AM<![CDATA[FDA’s New Pilot Program and Real-Time Review of Clinical Data]]> — Pharmaceutical Executive
- 5:00 AM · Drug Discovery World5:00 AMMediar selects Qureight to support systemic sclerosis trial — Drug Discovery World
- 3:49 AM · Pharmaceutical Technology3:49 AMFDA approves Enhertu for two HER2-positive early breast cancer indications — Pharmaceutical Technology
May 17, 2026
- 8:00 PM · Nature Biotechnology8:00 PMIntellia heads to FDA with first in vivo CRISPR-based gene editing therapy — Nature Biotechnology
- 7:00 AM · Ars Technica — Science7:00 AMA revolutionary cancer treatment could transform autoimmune disease — Ars Technica — Science